Skip to main content
Fig. 3 | Cancer Communications

Fig. 3

From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Fig. 3

OS following R–CVP and rituximab-maintenance therapy in the intent-to-treat population. Kaplan–Meier plot of OS for patients with advanced MZL treated with rituximab-maintenance following first-line R–CVP therapy. MZL marginal zone lymphoma, OS overall survival, R–CVP rituximab cyclophosphamide vincristine prednisolone

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us